Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Rapamycin (Sirolimus): Specific mTOR Inhibitor for Cancer...

    2026-01-02

    Rapamycin (Sirolimus): Specific mTOR Inhibitor for Cancer and Immunology Research

    Executive Summary: Rapamycin (Sirolimus) is a macrolide compound that binds FKBP12 to inhibit the mechanistic target of rapamycin (mTOR), a central regulator of cell growth and metabolism [APExBIO A8167]. It demonstrates high potency with an IC50 of ~0.1 nM in cell-based assays [Xie et al., 2020]. Rapamycin modulates key pathways including AKT/mTOR, ERK, and JAK2/STAT3, leading to apoptosis and reduced proliferation, notably in HGF-stimulated lens epithelial cells. In vivo, dosing at 8 mg/kg (i.p., every other day) enhances survival and slows disease progression in mitochondrial disease models. The compound is insoluble in water but highly soluble in DMSO (≥45.7 mg/mL) and ethanol (≥58.9 mg/mL, with ultrasonic treatment).

    Biological Rationale

    The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status. mTOR controls cell growth, proliferation, metabolism, and autophagy [Xie et al., 2020]. Dysregulation of mTOR signaling is implicated in cancer, metabolic disorders, and immune dysfunction. Targeted inhibition of mTOR has become a central strategy in both basic biomedical research and therapeutic development. Rapamycin, first identified as an antifungal and immunosuppressive agent, is now recognized as a gold-standard, specific inhibitor of mTOR and is widely used to dissect mTOR-dependent processes in cell biology, oncology, and immunology [Rapamycin: Specific mTOR Inhibitor for Cancer...]. This article provides a deep-dive into the mechanistic, quantitative, and translational evidence base for Rapamycin (Sirolimus) as supplied by APExBIO (A8167).

    Mechanism of Action of Rapamycin (Sirolimus)

    Rapamycin exerts its biological effects by binding intracellular FK-binding protein 12 (FKBP12), forming a binary complex. This complex specifically binds and inhibits mTOR complex 1 (mTORC1), blocking its kinase activity [APExBIO]. As a result, downstream phosphorylation events in multiple signaling pathways are suppressed:

    • AKT/mTOR pathway: Inhibition leads to reduced cell growth and proliferation.
    • ERK pathway: Downregulated, contributing to decreased mitogenic signaling.
    • JAK2/STAT3 pathway: Suppressed, resulting in reduced transcription of survival and proliferation genes.

    In HGF-stimulated lens epithelial cells, Rapamycin interrupts these pathways, inducing apoptosis and inhibiting proliferation [Xie et al., 2020]. The selectivity of Rapamycin for mTORC1 over mTORC2 is well-documented, although chronic exposure can affect mTORC2 in certain contexts [The Benchmark mTOR Inhibitor for Cell Signaling].

    Evidence & Benchmarks

    • Rapamycin demonstrates a cell-based IC50 of approximately 0.1 nM, indicating extremely high potency in mTOR inhibition (Xie et al., 2020).
    • Solubility is ≥45.7 mg/mL in DMSO and ≥58.9 mg/mL in ethanol (ultrasonic treatment), supporting versatility in assay workflows (APExBIO).
    • Intraperitoneal administration of 8 mg/kg every other day improves survival and slows progression in murine mitochondrial disease models (Advanced mTOR Inhibitor for Signaling & Disease Models).
    • Suppresses cell proliferation and induces apoptosis in HGF-stimulated lens epithelial cells by inhibiting AKT/mTOR, ERK, and JAK2/STAT3 (Xie et al., 2020).
    • Widely adopted as an immunosuppressant in transplantation medicine and as a research tool in autophagy and cancer biology (Rapamycin: Specific mTOR Inhibitor for Cancer...).

    Applications, Limits & Misconceptions

    Rapamycin (Sirolimus) is a foundational reagent for dissecting mTOR-dependent signaling in oncology, immunology, and mitochondrial biology. Its high specificity and reproducibility have led to its adoption as a reference standard in mTOR pathway research [Precision mTOR Inhibition for Advanced Models]. This article extends prior work by providing granular, quantitative parameters and highlighting best practices for storage, solubility, and in vivo dosing, building on the workflows described in [Leveraging Rapamycin for Reproducible Cell Assays].

    • Cancer research: Used to block proliferation and survival signaling.
    • Immunology: Investigates autophagy, T cell activation, and macrophage function.
    • Mitochondrial disease: Modulates metabolic and neuroinflammatory pathways in models such as Leigh syndrome.
    • Autophagy studies: Benchmarks for mTOR-dependent regulation of autophagosome-lysosome fusion, as shown in macrophage models (Xie et al., 2020).

    Common Pitfalls or Misconceptions

    • Rapamycin is insoluble in water; improper solvent selection leads to precipitation and loss of activity (APExBIO).
    • Long-term storage of solutions is not recommended; use freshly prepared stock for experimental reproducibility.
    • Chronic Rapamycin exposure may affect mTORC2 in some cell types, deviating from its canonical mTORC1 selectivity.
    • Not all cell types or disease models respond equally; dose and schedule optimization are critical for in vivo outcomes.
    • Rapamycin is not a broad-spectrum kinase inhibitor; activity is highly specific to mTOR complexes.

    Workflow Integration & Parameters

    Solubility & Handling: Dissolve Rapamycin (Sirolimus) at ≥45.7 mg/mL in DMSO or ≥58.9 mg/mL in ethanol (with ultrasonic treatment). Do not use aqueous buffers for stock solutions due to insolubility. Store desiccated at -20°C and avoid repeated freeze-thaw cycles. Prepare working aliquots fresh before each assay [APExBIO].

    In Vitro Use: Typical working concentrations range from 0.1 nM to 100 nM in cell-based assays. Confirm mTOR pathway inhibition by Western blotting for p-S6K or p-4EBP1. Use cell viability and apoptosis markers for endpoint validation.

    In Vivo Use: For mouse models, 8 mg/kg administered intraperitoneally every other day is a validated regimen for mitochondrial disease, but dosing should be titrated for other models.

    This article clarifies solvent compatibility and experimental parameters, extending the troubleshooting guidance found in [Leveraging Rapamycin for Reproducible Cell Assays].

    Conclusion & Outlook

    Rapamycin (Sirolimus) remains the reference mTOR inhibitor for dissecting cellular growth, metabolism, autophagy, and disease progression. APExBIO's A8167 formulation enables consistent results across cancer, immunology, and mitochondrial disease research. Quantitative solubility, dosing, and storage parameters ensure high reproducibility. Ongoing research is uncovering additional roles for mTOR inhibition in immunity and neurodegeneration. For detailed protocols and reagent specifications, visit the APExBIO Rapamycin (Sirolimus) product page.

    This article extends previous reviews by providing atomic, parameterized, and citation-backed guidance for integrating Rapamycin (Sirolimus) into advanced research workflows.